Cocrystal Pharma, Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

COCP$1.03-6.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	December 31,
2025 · 2024
Cash flows from operating activities:
Net loss		$(8,831)	$(17,504)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		72	126
Right of use assets		304	320
Stock-based compensation		270	643
Change in operating lease liabilities		(301)	(210)
Changes in operating assets and liabilities:
Tax credit receivable		509	(325)
Prepaid expenses and other current assets		102	1,343
Deposits		(66)	17
Accounts payable and accrued expenses		(251)	(895)
Net cash used in operating activities		(8,192)	(16,485)
Investing activities:
Purchases of property and equipment		(12)	(8)
Net cash used in investing activities		(12)	(8)
Financing activities:
Proceeds from the sale of common stock under ATM		154	-
Proceeds from sale of common stock and warrants, net of transaction costs		5,215	-
Net cash provided by financing activities		5,369	-
Net decrease in cash and restricted cash		(2,835)	(16,493)
Cash and restricted cash at beginning of period		9,935	26,428
Cash and restricted cash at end of period		$7,100	$9,935
Supplemental disclosure:
Non-cash investing and financing activities
Initial recognition of right-of-use assets and lease liabilities	$	-	$163

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.